Introduction
============

Intervertebral disc (IVD) degeneration (IDD) is considered a primary contributor to disc degeneration disease and is associated with lower back pain ([@b1-etm-0-0-6884]), which has become a serious public health issue and causes an enormous economic burden ([@b2-etm-0-0-6884]--[@b5-etm-0-0-6884]). Despite its significant clinical importance and prevalence, and its extensive impact on general health, current clinical management techniques, which include standard or endoscopic lumbar discectomy and intradiscal thermal annuloplasty, are associated with a substantial amount of recurrence ([@b6-etm-0-0-6884]--[@b9-etm-0-0-6884]). In addition, lumbar fusion increases the risk of adjacent segment degeneration ([@b10-etm-0-0-6884]).

Comprehensive knowledge of the mechanisms underlying IDD is critical for the development of successful therapeutic strategies. Over decades of research, increasing attention has been paid to the molecular mechanisms underlying IDD. Notable improvements in the knowledge of the pathological processes have been achieved ([@b11-etm-0-0-6884]), with multifactorial bioprocesses proven to contribute to IDD ([@b12-etm-0-0-6884]).

However, an enormous number of different molecules that interact with each other are associated with IDD, indicating that the pathological process is highly complex. In the abovementioned previous studies, only a small number of molecular factors have been investigated via classic experimental approaches, and thus, the current understanding of the molecular mechanisms involved in the initiation and progression of IDD remains limited. Therefore, clinical strategies remain limited, and the development of novel therapeutics depends on acquiring further insight into the molecular basis and pathophysiology underlying IDD.

The IVD is a complex structure, comprising fibrocartilaginous annulus fibrosis (AF) on the outside and highly gelatinous nucleus pulposus (NP) on the inside. The biochemical characteristics of IDD include extracellular matrix (ECM) degradation ([@b13-etm-0-0-6884],[@b14-etm-0-0-6884]). The ECM of IVDs consists primarily of collagen type III in the inner AF, type I in the outer AF and type II in the NP ([@b15-etm-0-0-6884]--[@b17-etm-0-0-6884]). The biological structure differs between AF and NP, and this difference was hypothesized to lead to different pathological processes in tissues from these two regions of the IVD during degeneration. The present study assessed possible differences in gene expression between the AF and NP in IDD by performing a bioinformatics analysis of gene expression profiles of AF and NP from degenerated IVDs.

Materials and methods
=====================

### Acquisition of expression data

The primary dataset GSE70362 was downloaded from the Gene Expression Omnibus (GEO) database (<http://www.ncbi.nlm.nih.gov/geo>). The GSE70362 dataset, which is based on the Affymetrix GPL17810 platform (HG-U133_Plus_2; Affymetrix; Thermo Fisher Scientific Inc., Waltham, MA, USA), was uploaded by Kazezian *et al* ([@b18-etm-0-0-6884]) in 2015. It contains the gene expression data for 48 IVD tissues, including 24 AF and 24 NP paired samples. The original signal intensity data in CEL format files (annotation edition information), matrix files and classifications based on the Thompson grading system ([@b19-etm-0-0-6884]) were downloaded. A total of 8 samples (GSM1725800, −1725801, −1725810, −1725811, −1725814, −1725815, −1725822 and −1725823) were discarded, as all of them were classified as Thompson grade I and were considered healthy. The remaining 40 samples were classified as Thompson grade I--II to V and consisted of 20 AF samples and 20 NP samples. To annotate the data, the original probe IDs were transformed into Gene symbol and Entrez IDs. Any probes that were not mapped to any GeneID or that were not identified were discarded.

### Identification of differentially expressed genes (DEGs)

A significance analysis of the microarray data was performed by using GeneSpring GX 11.5 software (Agilent Technologies, Inc., Santa Clara, CA, USA) to identify DEGs. After pre-processing the initial data via the Robust Multi-array Average procedure, the probe sets with intensity values between 20 and 100% were retained. For statistical analysis, an unpaired t-test was performed with a threshold P-value of 0.05 and absolute fold change (FC) of 2, and a Benjamini-Hochberg procedure for multiple testing was applied. Multiexperiment Viewer software (version 4.9.0; <http://mev.tm4.org/>) was used to construct a heat map of the DEGs identified.

### Enrichment analysis

DEGs were analyzed using online tools in Metascape (<http://metascape.org/>). Functional enrichment was performed in 3 categories of GO terms: Biological process (BP), molecular function (MF) and cellular component (CC). Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment was also performed. All genes in the genome were used as the enrichment background. Terms with a P-value of \<0.01, a minimum count of 3 and an enrichment factor of \>1.5 (the enrichment factor is the ratio of the observed count to the count expected by chance) were collected and grouped into clusters based on their membership similarities. More specifically, P-values were calculated based on the cumulative hypergeometric distribution. Q-values were calculated using the Benjamini-Hochberg procedure to account for multiple testing. Kappa scores were used as the similarity metric when performing hierarchical clustering of the enriched terms; sub-trees with a similarity of \>0.3 were considered a cluster. The most significant term within a cluster was selected as the one representing the cluster.

### Protein-protein interaction (PPI) network

To evaluate potential PPIs, DEGs were mapped using the Search Tool for the Retrieval of Interacting Genes (STRING; <http://string-db.org>) under the default settings; nodes lacking a connection in the network were excluded. Subsequently, a PPI network with a combined interaction score of \>0.4 was constructed by using Cytoscape software (version 3.6.3; <http://www.cytoscape.org/>). DEGs with a degree centrality of \>5.0 were identified as hub genes by using the plug-in CentiScaPe. The MCODE plug-in was applied to identify significant modules with the following criteria: 'Degree cutoff=2', 'node score cutoff=0.2', 'k-core=2' and 'max depth=100'.

Results
=======

### DEGs

A total of 1,514 genes were identified to be significantly differently expressed between AF and NP samples (P\<0.05). Of these, 863 genes were downregulated and 651 genes were upregulated. Further analysis identified 87 genes as DEGs with an absolute FC of \>2. The DEGs accounted for 0.16% of the total transcriptome ([Fig. 1](#f1-etm-0-0-6884){ref-type="fig"}). Among these 87 DEGs, 49 were upregulated and 38 were downregulated. The DEGs were ranked according to their FC, and the top 10 DEGs are listed in [Table I](#tI-etm-0-0-6884){ref-type="table"}. [Fig. 2](#f2-etm-0-0-6884){ref-type="fig"} presents the hierarchical clustering of the DEGs, with the original data normalized using the z-score to indexes between-3 and 3.

Based on the GO enrichment, the DEGs were enriched in 221 terms in the category BP, 7 in the category CC and 13 in the category MF. The top 30 GO terms in which the DEGs were enriched according to the gene count are presented in [Fig. 3](#f3-etm-0-0-6884){ref-type="fig"} and [Table II](#tII-etm-0-0-6884){ref-type="table"}. The DEGs were significantly enriched in a total of 8 KEGG pathways as presented in [Fig. 4](#f4-etm-0-0-6884){ref-type="fig"} and [Table III](#tIII-etm-0-0-6884){ref-type="table"}.

Gene ontology enrichment revealed that these DEGs were mainly involved in the inflammatory response, the extracellular matrix and RNA polymerase II transcription factor activity. Pathway enrichment revealed that the DEGs were mainly involved in the transforming growth factor (TGF-β) and estrogen signaling pathways. Matrix metalloproteinase (MMP)1 and interleukin (IL)6 were included in the genes enriched in rheumatoid arthritis, whereas bone morphogenetic protein (BMP)2 and thrombospondin 1 (THBS1) were among the genes enriched in the TGF-β signaling pathway.

### PPI network and module

As presented in [Fig. 5](#f5-etm-0-0-6884){ref-type="fig"}, the PPI network comprised 40 connected nodes and 50 edges, and IL6, THBS1, forkhead box (FOX)A2, BMP2, estrogen receptor (ESR)1, heat shock protein A4, suppressor of cytokine signaling (SOCS)3 and early growth response 1 were identified as hub genes. One significant module containing 10 nodes and 15 edges was screened out ([Fig. 6](#f6-etm-0-0-6884){ref-type="fig"}).

Discussion
==========

DNA chips allow for the simultaneous detection of the expression of tens of thousands of genes at one time in a single DNA microarray, which facilitates the further identification of DEGs in pathological processes and investigations applying this technology may substantially enhance the knowledge of the molecular mechanisms of IDD. As the DNA microarray has become popular in recent years, there has been an increased use of transcriptomic approaches in the investigation of the pathophysiology of IDD at the molecular level.

Analysis of the expression spectrum of AF tissues in a previous study revealed that, compared to AF in less degenerated IVDs (Thompson grades I--III), bradykinin receptor B1, calcitonin gene-related peptide and catechol-O-methyltransferase (genes associated with pain), as well as nerve growth factor, were significantly upregulated in more degenerated IVDs (grades IV and V); in addition, numerous genes encoding chemokines and pro-inflammatory cytokines were markedly affected ([@b20-etm-0-0-6884]). Another microarray analysis indicated differential expression of proteins that bind aspirin in degenerate disc specimens, with higher levels detected in the more degenerated IVDs (grade IV) than in the less degenerated ones (grades I, II and III) ([@b21-etm-0-0-6884]). Tsai *et al* ([@b22-etm-0-0-6884]) reported on 14 DEGs, including periostin, insulin-like growth factor binding protein (IGFB)P6 and MMP-2, in the NP of degenerated IVDs. Via a genome-wide analysis, Gruber *et al* ([@b23-etm-0-0-6884]) identified 424 DEGs in the NP from degenerate IVDs compared with that in normal NP cells and proposed critical genes associated with disc degeneration; these were mainly involved in the ECM, ECM proteolysis, cell proliferation and apoptosis, and also comprised growth factors and inflammatory mediators. He *et al* ([@b24-etm-0-0-6884]) compared gene expression data of degenerated IVDs with those of non-degenerated samples and identified 961 DEGs, including 846 DEGs in disc tissues of grade-III IVDs and 1,137 in disc tissues of grade-IV IVDs. They hypothesized that tumor protein 53 has an important role in IDD by impacting neovascularization and infiltration in AF, while ubiquitin C participated by blocking of cell proliferation in the AF. Kazezian *et al* ([@b18-etm-0-0-6884]) obtained microarray data from AF tissues from degenerated and non-degenerated IVDs and identified 238 DEGs in the AF of degenerated IVDs. The dysregulated genes were mainly enriched in the areas of cell proliferation and cellular growth, and were adversely disrupted by IGFBP3 and interferon induced protein with tetratricopeptide repeats 3. Tang *et al* ([@b25-etm-0-0-6884]) identified 53 DEGs in degenerated IVDs compared with non-degenerated ones, of which 16 genes were downregulated and 37 were upregulated; bioinformatics analysis revealed that the DEGs were associated with TGF-β and the ECM, and MMP2 was indicated to have the highest degree of interaction in the PPI network. Guo *et al* ([@b26-etm-0-0-6884]) identified 35 genes that were differentially expressed in AF and NP of degenerated IVDs compared with non-degenerated tissues by analyzing microarray data. Their results suggested that collagen type VI α 2 chain, integrin-binding sialoprotein, RAP1A and FOXF2 serve important roles in the focal adhesion signaling pathway associated with IDD and that interferon induced protein with tetratricopeptide repeats 1, −2 and −3 may accelerate degenerative processes by affecting ECM organization.

The original study that provided the microarray dataset GSE70362 focusing on AF identified 238 dysregulated genes indegenerated AF in comparison with non-degenerated AF ([@b24-etm-0-0-6884]). These dysregulated genes were enriched in the areas of cellular growth, cell proliferation and inflammatory response, thus confirming that the interferon signaling pathway was significantly dysregulated and activated ([@b24-etm-0-0-6884]). However, all previous studies employing DNA microarrays to investigate the molecular mechanisms of IDD compared degenerated AF, NP or 'discs' with non-degenerated tissues. Among these studies, only one noted a similarity of genes involved in AF and NP degeneration by enrichment analysis and a PPI network, and to the best of our knowledge, no previous study has examined whether the degeneration of AF and NP proceeds via different pathophysiological processes at the cellular and the molecular level. Of note, Schubert *et al* ([@b27-etm-0-0-6884]) assessed AF and NP tissues from low-level degenerated disks and reported that 267 DEGs were upregulated in AF compared with NP tissues and that 52 DEGs were more highly expressed in NP compared with AF tissues. The authors further identified ankyrin repeat domain 29, adhesion G protein-coupled receptor L4, endomucin, LIM domain binding 2 and olfactomedin like 2A as AF markers, and ArfGAP with RhoGAP domain, ankyrin repeat and PH domain 2 (ARAP2), cyclin dependent kinase inhibitor 2B (CDKN2B), defensin β1, desmocollin 3 (DSC3) and erythroferrone as NP markers. Those identified as AF markers were upregulated in AF and those identified as NP markers were upregulated in NP. These results are consistent with those of the present study, which identified the upregulation of the NP markers ARAP2, CDKN2B and DSC3 in AF compared with those in NP tissues.

The present study uncovered several different pathophysiological aspects of AF and NP degeneration at the molecular level. These results enhance the current knowledge of the molecular mechanisms of IDD. The present analysis of 20 AF and 20 NP samples from the GSE70362 dataset retrieved from the GEO identified a total of 87 DEGs with P\<0.05 and FC\>2 in AF compared to NP samples including 48 upregulated and 39 downregulated DEGs. Enrichment analysis indicated that these DEGs were mainly involved in the GO terms of inflammatory response, ECM and RNA polymerase II transcription factor activity, as well as in the KEGG pathways of TGF-β and estrogen signaling. KEGG pathway analysis revealed that MMP1 and IL6 were included in the genes enriched in rheumatoid arthritis, whereas BMP2 and THBS1 were among the genes enriched in the TGF-β signaling pathway. In the PPI network, IL6 was identified as the central hub gene.

The expression of MMP1, which has been identified in 91% of IVDs, increases in degenerated IVDs ([@b28-etm-0-0-6884]). The significantly higher levels of MMP1 in degenerated IVDs compared with those in normal discs indicate a positive correlation between MMP1 and IDD ([@b29-etm-0-0-6884]). The expression of MMP1 was reported to be markedly associated with clefts and tears of AF and NP ([@b30-etm-0-0-6884],[@b31-etm-0-0-6884]). However, most of the abovementioned previous studies assessed 'disc tissues' or 'disc specimens' without differentiating between AF and NP. MMP1 is a type of collagenase with the characteristic function of cleaving interstitial collagens I, II and III ([@b32-etm-0-0-6884],[@b33-etm-0-0-6884]). MMP1 has the greatest degradation activity toward collagen III ([@b34-etm-0-0-6884]). Collagen III is the most common type of collagen in the inner AF, whereas the outer AF mainly consists of collagen I, and the NP mainly consists of collagen II ([@b15-etm-0-0-6884]--[@b17-etm-0-0-6884],[@b35-etm-0-0-6884]). This pattern of collagen distribution and the different effects of MMP1 on the degradation of these collagens may explain for the upregulation of MMP1 in AF compared to NP observed in the present study.

BMP2 downregulates MMP13 and upregulates aggrecan, sex-determining region Y box 6 and type II collagen, and thus, it has an anti-catabolic effect on ECM enzymes in AF and NP ([@b36-etm-0-0-6884]). In NP and the inner AF, BMP2 increases aggrecan, as well as type I and II collagen, while simultaneously increasing proteoglycan synthesis and stimulating mitogenesis in the outer AF ([@b37-etm-0-0-6884],[@b38-etm-0-0-6884]). The biological effect of estrogen mainly occurs through ESR1 and −2 ([@b39-etm-0-0-6884]), with ESR2 as the predominant ESR ([@b40-etm-0-0-6884]). Basic research has confirmed that ESR1 is negatively correlated with the aggravation of NP degeneration ([@b41-etm-0-0-6884]). The present study revealed that the expression of ESR1 is upregulated in degenerated AF vs. NP; however, the detailed role of ESR1 in this context requires further investigation. The anti-angiogenic characteristics of THBS1 have long been known ([@b42-etm-0-0-6884]). A previous study reported strong immunoreactivity for THBS1 in the outer AF, suggesting that THBS1 may contribute to the avascular status of the IVD ([@b43-etm-0-0-6884]).

An inflammatory response is thought to initiate IDD, and pro-inflammatory molecules, including IL6, secreted by IVD cells are considered to mediate IDD ([@b44-etm-0-0-6884]). In addition, IL6 was identified as a hub gene in the PPI network that was constructed as part of the present study. Accordingly, it may be speculated that IL6 has a key role in IDD. This speculation is consistent with another study suggesting that IL6 is critical in IDD ([@b45-etm-0-0-6884]). Herniated IVDs have been reported to spontaneously produce IL6 ([@b46-etm-0-0-6884]). IL6 downregulates characteristic ECM proteins, including aggrecan and collagen II, in NP ([@b47-etm-0-0-6884]). This regulatory effect was specifically located to the site of herniation ([@b48-etm-0-0-6884],[@b49-etm-0-0-6884]). Shamji *et al* ([@b50-etm-0-0-6884]) detected higher IL6 expression in herniated IVD tissues than in non-degenerated autopsy samples, whereas Lee *et al* ([@b51-etm-0-0-6884]) identified no significant differences in IL6 expression levels between degenerated IVDs and herniated NP. Most of these studies were based on herniated IVDs rather than on degenerated IVDs and did not distinguish between AF and NP specimens. None of these studies mentioned the difference in IL6 expression levels between AF and NP. In the present study, IL6 expression was upregulated with an FC of 2.27 in AF vs. NP tissues; the molecular biological implications of this observation require further investigation. With regard to the genes enriched in terms/pathways associated with the inflammatory response, except for the participation of IL6, BMP2, ESR1 and THBS1 in IDD, limited data are available to suggest the biological actions of F2R like trypsin receptor 1, orosomucoid 1 and −2, serpin family F member 1, serpin family A member 1, SERPINA1, prostaglandin E receptor 4, phospholipase A2 group IVC and SOCS3 in IDD.

In conclusion, the present bioinformatics study revealed DEGs and their enriched functions/pathways in the AF and NP during IDD. A novel integrated understanding of certain molecular mechanisms of IDD was obtained. The different distribution patterns of collagen types and different degradation efficiencies of MMP1 on these collagen types may contribute to the upregulation of MMP1 in AF compared with that in NP. IL6 may be a key factor accounting for the different processes of degeneration in AF and NP. BMP2, ESR1 and THBS1 may also be involved in the different pathological changes observed in AF and NP. The present study is based on information available from a public database rather than from experimentation, and the biological implications of these different gene expression patterns require further investigation.
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![Volcano plot displaying the DEGs. The expression levels of 1,514 genes were significantly different between AF and NP (P\<0.05). A total of 87 genes were identified as DEGs (P\<0.05, absolute FC\>2; red squares). The P-value was adjusted using the Benjamini-Hochberg procedure. FC, fold change; NP, nucleus pulposus; AF, annulus fibrosus; DEG, differentially expressed gene.](etm-16-06-5031-g00){#f1-etm-0-0-6884}

![Heatmap displaying hierarchical clustering of the 87 differentially expressed genes in annulus fibrosus and nucleus pulposus (red, upregulated; green, downregulated). The original data were normalized using the z-score to indexes between −3 and 3.](etm-16-06-5031-g01){#f2-etm-0-0-6884}

![The top 30 ranked GO terms according to gene count. 'Qvalue' is the P-value adjusted using the Benjamini-Hochberg procedure. 'Log (Qvalue)' is the log 10 of the q-value. 'Gene count' is the number of genes enriched in a GO term. 'Gene ratio' is the percentage of total DEGs in the given GO term (only input genes with at least one GO term annotation were included in the calculation). GO, gene ontology; BP, biological process; MF, molecular function; CC, cellular component.](etm-16-06-5031-g02){#f3-etm-0-0-6884}

![Kyoto Encyclopedia of Genes and Genomes pathway enrichment analysis. hsa, Homo sapiens; TGF, transforming growth factor; TNF, tumor necrosis factor; TRP, transient receptor potential.](etm-16-06-5031-g03){#f4-etm-0-0-6884}

![Protein-protein interaction network of differentially expressed genes. All nodes with a combined interaction score of \>0.4 are displayed. The blue nodes have a central role with a degree of \>5.0.](etm-16-06-5031-g04){#f5-etm-0-0-6884}

![Significant modules were screened with the following criteria: Degree centrality cutoff, 2; node score cutoff, 0.2; k-core, 2; max depth, 100.](etm-16-06-5031-g05){#f6-etm-0-0-6884}

###### 

Top 10 most highly dysregulated genes.

  Gene      Absolute FC   Regulation   P-value        Q-value^[a](#tfn1-etm-0-0-6884){ref-type="table-fn"}^
  --------- ------------- ------------ -------------- -------------------------------------------------------
  SPARCL1   5.77          Up           1.03×10^−4^    1.26×10^−2^
  MMP1      5.75          Up           1.32×10^−5^    4.34×10^−3^
  IBSP      5.16          Up           1.04×10^−3^    4.35×10^−2^
  RGS1      4.64          Down         5.30×10^−6^    2.44×10^−3^
  THBS1     4.25          Up           6.66×10^−10^   7.12×10^−6^
  FBLN1     4.18          Up           4.32×10^−8^    1.39×10^−4^
  EPB41L3   3.97          Down         6.48×10^−11^   1.77×10^−6^
  MEG3      3.82          Up           1.61×10^−6^    1.26×10^−3^
  HSPA6     3.65          Up           3.16×10^−4^    2.25×10^−2^
  IRX2      3.40          Up           2.02×10^−10^   2.76×10^−6^

The P-value was adjusted using the Benjamini-Hochberg procedure and was denoted as the Q-value. FC, fold change.

###### 

Top 30 enriched GO terms.

  Category   Term         Description                                                                      Log10(P)   Log10(Q)       Gene count   Genes
  ---------- ------------ -------------------------------------------------------------------------------- ---------- -------------- ------------ ---------------------------------------------------------------------------------------
  GO BP      GO:0006954   Inflammatory response                                                            −4.29      −1.23          12           BMP2, ESR1, F2RL1, IL6, ORM1, ORM2, SERPINF1, SERPINA1, PTGER4, THBS1, PLA2G4C, SOCS3
  GO BP      GO:0000122   Negative regulation of transcription by RNA polymerase II                        −4.11      −1.13          12           BMP2, EGR1, ESR1, DNAJB1, NR4A2, PRRX1, SHOX2, TBX3, FST, DKK1, NEDD4L, IRX2
  GO BP      GO:0001503   Ossification                                                                     −6.53      −2.19          11           BMP2, DLX5, IBSP, IL6, PTGER4, SHOX2, STC1, IFITM1, GPNMB, DKK1, RSPO2
  GO CC      GO:0031012   Extracellular matrix                                                             −4.79      −1.52          11           FBLN1, IBSP, MMP1, MMP10, NID1, ORM1, ORM2, SERPINF1, SERPINA1, THBS1, SPARCL1
  GO BP      GO:0030155   Regulation of cell adhesion                                                      −4.28      −1.23          11           BMP2, CD80, FBLN1, FOXA2, IBSP, IL6, NID1, THBS1, GPNMB, APBB1IP, DOCK8
  GO BP      GO:0002366   Leukocyte activation involved in immune response                                 −4.00      −1.04          11           CD80, F2RL1, HSPA6, IL6, MGST1, ORM1, ORM2, SERPINA1, PTGER4, PTPRB, APBB1IP
  GO BP      GO:0002263   Cell activation involved in immune response                                      −3.97      −1.03          11           CD80, F2RL1, HSPA6, IL6, MGST1, ORM1, ORM2, SERPINA1, PTGER4, PTPRB, APBB1IP
  GO BP      GO:0007178   Transmembrane receptor protein serine/threonine kinase signaling pathway         −6.02      −1.99          10           BMP2, CDKN2B, DLX5, EGR1, THBS1, FST, DKK1, HTRA3, PPM1L, RBPMS2
  GO BP      GO:0048598   Embryonic morphogenesis                                                          −3.91      −1.00          10           DLX5, FOXA2, PRRX1, SHOX2, TBX3, SOCS3, DKK1, IRX2, RSPO2, RBPMS2
  GO BP      GO:0051345   Positive regulation of hydrolase activity                                        −3.07      −5.89×10^−1^   10           ASPH, BMP2, ESR1, F2RL1, FBLN1, DNAJB1, RGS1, RGS5, DOCK8, ARAP2
  GO BP      GO:0055082   Cellular chemical homeostasis                                                    −3.06      −5.89×10^−1^   10           CLIC2, ESR1, F2RL1, FOXA2, SERPINF1, STC1, UCP2, DMXL2, NEDD4L, CEMIP
  GO BP      GO:0019221   Cytokine-mediated signaling pathway                                              −2.87      −5.39×10^−1^   10           CD80, EGR1, F2RL1, IL6, MMP1, IFITM1, SOCS2, SOCS3, TRIM22, IFITM2
  GO BP      GO:0045859   Regulation of protein kinase activity                                            −2.86      −5.38×10^−1^   10           BMP2, CDKN2B, EGR1, THBS1, SOCS2, SOCS3, DIRAS3, PPM1E, DKK1, CEMIP
  GO BP      GO:0001817   Regulation of cytokine production                                                −3.05      −5.89×10^−1^   9            CD80, EGR1, F2RL1, IL6, ORM1, ORM2, PTGER4, THBS1, GPNMB
  GO BP      GO:0045936   Negative regulation of phosphate metabolic process                               −3.11      −5.89×10^−1^   9            CDKN2B, F2RL1, FBLN1, FOXA2, SOCS2, SOCS3, GABBR2, PPM1E, DKK1
  GO BP      GO:0010563   Negative regulation of phosphorus metabolic process                              −3.10      −5.89×10^−1^   9            CDKN2B, F2RL1, FBLN1, FOXA2, SOCS2, SOCS3, GABBR2, PPM1E, DKK1
  GO BP      GO:0048729   Tissue morphogenesis                                                             −2.96      −5.74×10^−1^   9            BMP2, ESR1, SHOX2, STC1, TBX3, SOCS3, DKK1, IRX2, RSPO2
  GO BP      GO:0071363   Cellular response to growth factor stimulus                                      −2.83      −5.20×10^−1^   9            BMP2, CDKN2B, DLX5, EGR1, IBSP, THBS1, DKK1, HTRA3, RBPMS2
  GO BP      GO:0001816   Cytokine production                                                              −2.75      −4.86×10^−1^   9            CD80, EGR1, F2RL1, IL6, ORM1, ORM2, PTGER4, THBS1, GPNMB
  GO BP      GO:0070848   Response to growth factor                                                        −2.71      −4.76×10^−1^   9            BMP2, CDKN2B, DLX5, EGR1, IBSP, THBS1, DKK1, HTRA3, RBPMS2
  GO BP      GO:0060322   Head development                                                                 −2.56      −3.84×10^−1^   9            ASPH, BMP2, DLX5, FOXG1, HNMT, NR4A2, POU3F3, TBX3, DKK1
  GO MF      GO:0000981   RNA polymerase II transcription factor activity, sequence-specific DNA binding   −2.44      −3.05×10^−1^   9            DLX5, EGR1, ESR1, FOXG1, FOXA2, NR4A2, PRRX1, TBX3, IRX2
  GO MF      GO:0044877   Protein-containing complex binding                                               −2.36      −2.71×10^−1^   9            FBLN1, GNAL, IBSP, NID1, THBS1, SPARCL1, GPNMB, FST, ADGRG6
  GO BP      GO:0051223   Regulation of protein transport                                                  −2.36      −2.70×10^−1^   9            F2RL1, FOXA2, HNMT, IL6, ORM1, ORM2, PTGER4, UCP2, CEMIP
  GO BP      GO:0001649   Osteoblast differentiation                                                       −5.72      −1.99          8            BMP2, DLX5, IBSP, IL6, SHOX2, IFITM1, GPNMB, RSPO2
  GO BP      GO:0001819   Positive regulation of cytokine production                                       −3.61      −8.12×10^−1^   8            CD80, EGR1, F2RL1, IL6, ORM1, ORM2, PTGER4, THBS1
  GO BP      GO:0042110   T cell activation                                                                −3.27      −6.41×10^−1^   8            CD80, EGR1, F2RL1, IL6, PTGER4, GPNMB, APBB1IP, DOCK8
  GO BP      GO:0042326   Negative regulation of phosphorylation                                           −3.19      −6.01×10^−1^   8            CDKN2B, F2RL1, FBLN1, FOXA2, SOCS2, SOCS3, PPM1E, DKK1
  GO BP      GO:0001501   Skeletal system development                                                      −3.08      −5.89×10^−1^   8            BMP2, DLX5, PRRX1, PTGER4, SHOX2, STC1, TBX3, RSPO2
  GO BP      GO:0002446   Neutrophil mediated immunity                                                     −3.02      −5.89×10^−1^   8            F2RL1, HSPA6, IL6, MGST1, ORM1, ORM2, SERPINA1, PTPRB

GO, gene ontology; BP, biological process; MF, molecular function; CC, cellular component.

###### 

KEGG pathway enrichment analysis.

  Term       Description                                  Log10(P)       Log10(Q)   Genes
  ---------- -------------------------------------------- -------------- ---------- ----------------------------
  hsa04350   TGF-β signaling pathway                      −3.426090165   −0.780     BMP2, CDKN2B, THBS1, FST
  hsa04915   Estrogen signaling pathway                   −3.172403712   −0.780     ESR1, HSPA6, GABBR2, CREB5
  hsa04917   Prolactin signaling pathway                  −2.542647382   −0.326     ESR1, SOCS2, SOCS3
  hsa05164   Influenza A                                  −2.272816914   −0.241     HSPA6, DNAJB1, IL6, SOCS3
  hsa04931   Insulin resistance                           −2.029682792   −0.228     IL6, SOCS3, CREB5
  hsa04668   TNF signaling pathway                        −2.018699722   −0.228     IL6, SOCS3, CREB5
  hsa05323   Rheumatoid arthritis Inflammatory mediator   −2.236138588   −0.241     CD80, IL6, MMP1
  hsa04750   Regulation of TRP channels                   −2.146268906   −0.231     F2RL1, PTGER4, PLA2G4C

The Q-value is the P-value adjusted using the Benjamini-Hochberg procedure. hsa, *Homo sapiens*; TGF, transforming growth factor; TNF, tumor necrosis factor; TRP, transient receptor potential.
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